LSE - Delayed Quote GBp

HUTCHMED (China) Limited (HCM.L)

232.50

+6.00

+(2.65%)

At close: May 2 at 3:22:32 PM GMT+1

HUTCHMED Highlights Data to be Presented at AACR Annual Meeting 2025

HONG KONG and SHANGHAI and FLORHAM PARK, N.J., April 24, 2025 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that new and updated data from several studies of compounds discovered by HUTCHMED including savolitinib, fruquintinib and surufatinib, which will be presented at the upcoming American Association of Cancer Research (AACR) Annual Meeting 2025, taking place on April 25-30, 2025 in Chicago, Illinois. Details of the presentations are as

GlobeNewswire 9 days ago

HCM

HMDCF
HUTCHMED Completes Patient Enrollment of a Phase II Registration Study of Savolitinib in Gastric Cancer in China

HONG KONG and FLORHAM PARK, N.J., April 22, 2025 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that it has completed enrollment of the registration phase of its Phase II trial of savolitinib in gastric cancer patients with MET amplification. This clinical trial is a single-arm, multi-center, open-label, Phase II registration study to evaluate the efficacy, safety and tolerability of savolitinib in treating gastric cancer or gastroesophageal

GlobeNewswire 11 days ago

HCM

HMDCF
$HUTCHMED Announces NMPA Conditional Approval for TAZVERIK® (tazemetostat) for the Treatment of Relapsed or Refractory Follicular Lymphoma$

HUTCHMED Announces NMPA Conditional Approval for TAZVERIK® (tazemetostat) for the Treatment of Relapsed or Refractory Follicular Lymphoma

— First and only EZH2 inhibitor approved by the NMPA — — HUTCHMED’s fourth product, and its first approval in hematological malignancies — HONG KONG and SHANGHAI and FLORHAM PARK, N.J., March 21, 2025 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that the New Drug Application (“NDA”) for TAZVERIK® (tazemetostat) has been granted conditional approval in China for the treatment of adult patients with relapsed or refractory (“R/R”) follicular

GlobeNewswire last month

HCM

HMDCF
HUTCHMED (China) Full Year 2024 Earnings: EPS Beats Expectations, Revenues Lag

HUTCHMED (China) ( LON:HCM ) Full Year 2024 Results Key Financial Results Revenue: US$630.2m (down 25% from FY 2023...

Simply Wall St. last month

HCM

HMDCF
Intended Retirement of Independent Non-executive Directors and changes of composition of board committees

HONG KONG and SHANGHAI and FLORHAM PARK, N.J., March 20, 2025 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED” or the “Company”) (Nasdaq/AIM:HCM, HKEX:13) today announces that Mr Paul Rutherford Carter and Mr Graeme Allan Jack, who have both served as Independent Non-executive Directors of the Company for more than eight years, have informed the Company that they would not seek re-election after retiring from the Board at the forthcoming annual general meeting of the Company to be held

GlobeNewswire last month

HCM

HMDCF
HUTCHMED (China) Ltd (HCM) (Q4 2024) Earnings Call Highlights: Achieving Profitability and ...

HUTCHMED (China) Ltd (HCM) reports a profitable year with significant sales growth and strategic global expansions, despite market challenges.

GuruFocus.com last month

HCM
HUTCHMED Highlights Savolitinib SAVANNAH Phase II and Other Data at European Lung Cancer Congress 2025

— SAVANNAH Phase II trial demonstrated high and durable response rates with savolitinib plus TAGRISSO® in MET-high lung cancer, representing a promising chemo-free oral treatment strategy to address mechanisms of resistance in the advanced setting — — Long-term survival benefit and safety observed in savolitinib Phase IIIb study in METex14 NSCLC — HONG KONG and SHANGHAI and FLORHAM PARK, N.J., March 20, 2025 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) toda

GlobeNewswire last month

HCM

HMDCF
HUTCHMED Reports 2024 Full Year Results and Provides Business Updates

65% oncology products revenue growth drove profitable operation and supported new ATTC platformHONG KONG and SHANGHAI and FLORHAM PARK, N.J., March 19, 2025 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”, the “Company” or “we”) (HKEX:13; Nasdaq/AIM:HCM) today reports its financial results for the year ended December 31, 2024 and provides updates on key clinical and commercial developments. HUTCHMED to host results webcasts today at 8:00 a.m. EDT / 12:00 noon GMT / 8:00 p.m. HKT in En

GlobeNewswire last month

HCM

HMDCF
HUTCHMED and Innovent Jointly Announce that the FRUSICA-2 Phase II/III Study of Fruquintinib and Sintilimab Combination Has Met its Primary Endpoint in Advanced Renal Cell Carcinoma in China

HONG KONG and SHANGHAI and FLORHAM PARK, N.J., March 19, 2025 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) and Innovent Biologics, Inc. (“Innovent”) (HKEX: 01801), today jointly announce that the FRUSICA-2 Phase II/III clinical trial evaluating fruquintinib in combination with sintilimab as second-line treatment for locally advanced or metastatic renal cell carcinoma (“RCC”) in China has met its primary endpoint of progression free survival (“PFS”) per RE

GlobeNewswire last month

HCM

HMDCF

IVBIY
HUTCHMED (China) (LON:HCM) shareholders have earned a 3.7% CAGR over the last three years

One simple way to benefit from the stock market is to buy an index fund. But if you choose individual stocks with...

Simply Wall St. last month

HCM

HMDCF
HUTCHMED Announces that it has Completed Enrollment of a Phase II Registration Study of Fanregratinib (HMPL-453) for Intrahepatic Cholangiocarcinoma in China

HONG KONG and SHANGHAI and FLORHAM PARK, N.J., March 06, 2025 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that it has completed enrollment of its a Phase II trial of fanregratinib (HMPL-453) for intrahepatic cholangiocarcinoma (“IHCC”) patients with fibroblast growth factor receptor (“FGFR”)2 fusion/rearrangement. The study is a single-arm, multi-center, open-label, Phase II registration study to evaluate the efficacy, safety and pharmaco

GlobeNewswire last month

HCM

HMDCF
HUTCHMED Announces Appointment of Independent Non-executive Director and Member of Board Committee

HONG KONG and SHANGHAI and FLORHAM PARK, N.J., March 05, 2025 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED” or the “Company”) (Nasdaq/AIM:HCM, HKEX:13) today announces that Mr Wong Tak Wai (Mr Alvin Wong) is appointed as an Independent Non-executive Director and a member of the Audit Committee of the Company with effect from March 6, 2025. Mr Wong has over 35 years of extensive experience in accounting, auditing and corporate finance. He has acted in a pivotal role in assisting comp

GlobeNewswire last month

HCM

HMDCF

0158.HK
HUTCHMED to Announce 2024 Final Results

HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Feb. 19, 2025 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; SEHK:13) will be announcing its final results for the year ended December 31, 2024 on Wednesday, March 19, 2025 at 7:00 am Eastern Daylight Time (EDT) / 11:00 am Greenwich Mean Time (GMT) / 7:00 pm Hong Kong Time (HKT). Analysts and investors are invited to join a conference call and audio webcast presentation with Q&A, conducted by HUTCHMED management. The Eng

GlobeNewswire 2 months ago

HCM

HMDCF
Hutchmed price target raised to $27 from $26 at BofA

BofA raised the firm’s price target on Hutchmed (HCM) to $27 from $26 and keeps a Buy rating on the shares. While noting it sees “some regulatory headwinds potentially ahead,” the firm keeps a Buy rating on the shares and cites higher revenue expectations for key assets after “strong performance in 2024” for its revised price target Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See Insiders’ Hot Stocks on TipRanks >> Read More on

TipRanks 2 months ago

HCM

HMDCF
HUTCHMED Announces NMPA Full Approval for ORPATHYS® (savolitinib) in China for Patients with Locally Advanced or Metastatic MET Exon 14 NSCLC

— Indication expands to include treatment-naïve patients — — The 2021 conditional approval in previously treated patients converted to full approval — HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Jan. 14, 2025 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that the supplemental New Drug Application for ORPATHYS® (savolitinib) has been granted approval by the China National Medical Products Administration (“NMPA”) for the treatment of adult

GlobeNewswire 3 months ago

HCM

HMDCF
Private equity firms are HUTCHMED (China) Limited's (LON:HCM) biggest owners and were rewarded after market cap rose by UK£120m last week

Key Insights The considerable ownership by private equity firms in HUTCHMED (China) indicates that they collectively...

Simply Wall St. 3 months ago

HCM

HMDCF
Hutchmed divests 45% interest in Shanghai Hutchison for $608M

Hutchmed (HCM) announces that it has entered into two agreements to divest its 45% equity interest in Shanghai Hutchison Pharmaceuticals for $608M in cash to GP Health Service Capital and Shanghai Pharmaceuticals. Hutchmed said it has been exploring opportunities to monetize the underlying value of SHPL, a “non-core, non-consolidated joint venture.” It added, “These transactions would allow Hutchmed to focus on its core business of discovering, developing and commercializing novel therapies for

TipRanks 3 months ago

HCM

HMDCF
HUTCHMED Announces NDA Acceptance in China with Priority Review Status for ORPATHYS® and TAGRISSO® Combination in Lung Cancer Patients with MET amplification After Progression on First-Line EGFR Inhibitor Therapy

HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Jan. 02, 2025 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that the New Drug Application (“NDA”) for the combination of ORPATHYS® (savolitinib) and TAGRISSO® (osimertinib) for the treatment of patients with locally advanced or metastatic epidermal growth factor receptor (“EGFR”) mutation-positive non-small cell lung cancer (“NSCLC”) with MET amplification after disease progression on first-line

GlobeNewswire 3 months ago

HCM

HMDCF
HUTCHMED Announces US$608 million Divestment of Non-Core Joint Venture

— HUTCHMED continues to deliver on its strategy outlined in November 2022 to create value, prioritize its portfolio and bring innovative medicines to patients globally — — Divestment proceeds to advance HUTCHMED’s pipeline and core innovative medicines business — — Focused R&D investment includes HUTCHMED’s proprietary antibody-targeted therapy conjugate platform, with first candidates expected to enter clinical trials in the second half of 2025 — HONG KONG and SHANGHAI and FLORHAM PARK, N.J., J

GlobeNewswire 3 months ago

HCM

HMDCF

SHPMF
HUTCHMED to Receive Milestone Payment from Takeda following First European Reimbursement for FRUZAQLA® (fruquintinib)

— US$10 million milestone payment to HUTCHMED follows first national reimbursement in Europe — — Follows June 2024 European approval of FRUZAQLA® (fruquintinib), the first novel oral targeted therapy in the EU for metastatic colorectal cancer regardless of biomarker status in over a decade — HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Dec. 12, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that it will receive a US$10 million milestone

GlobeNewswire 4 months ago

TAK

TKPHF

HCM

Performance Overview

Return	HCM.L	FTSE 100 (^FTSE)
YTD	-1.06%	+5.18%
1-Year	-25.00%	+5.19%
3-Year	-5.30%	+13.94%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

HUTCHMED (China) Limited (HCM.L)

HUTCHMED Highlights Data to be Presented at AACR Annual Meeting 2025

HUTCHMED Completes Patient Enrollment of a Phase II Registration Study of Savolitinib in Gastric Cancer in China

HUTCHMED Announces NMPA Conditional Approval for TAZVERIK® (tazemetostat) for the Treatment of Relapsed or Refractory Follicular Lymphoma

HUTCHMED (China) Full Year 2024 Earnings: EPS Beats Expectations, Revenues Lag

Intended Retirement of Independent Non-executive Directors and changes of composition of board committees

HUTCHMED (China) Ltd (HCM) (Q4 2024) Earnings Call Highlights: Achieving Profitability and ...

HUTCHMED Highlights Savolitinib SAVANNAH Phase II and Other Data at European Lung Cancer Congress 2025

HUTCHMED Reports 2024 Full Year Results and Provides Business Updates

HUTCHMED and Innovent Jointly Announce that the FRUSICA-2 Phase II/III Study of Fruquintinib and Sintilimab Combination Has Met its Primary Endpoint in Advanced Renal Cell Carcinoma in China

HUTCHMED (China) (LON:HCM) shareholders have earned a 3.7% CAGR over the last three years

HUTCHMED Announces that it has Completed Enrollment of a Phase II Registration Study of Fanregratinib (HMPL-453) for Intrahepatic Cholangiocarcinoma in China

HUTCHMED Announces Appointment of Independent Non-executive Director and Member of Board Committee

HUTCHMED to Announce 2024 Final Results

Hutchmed price target raised to $27 from $26 at BofA

HUTCHMED Announces NMPA Full Approval for ORPATHYS® (savolitinib) in China for Patients with Locally Advanced or Metastatic MET Exon 14 NSCLC

Private equity firms are HUTCHMED (China) Limited's (LON:HCM) biggest owners and were rewarded after market cap rose by UK£120m last week

Hutchmed divests 45% interest in Shanghai Hutchison for $608M

HUTCHMED Announces NDA Acceptance in China with Priority Review Status for ORPATHYS® and TAGRISSO® Combination in Lung Cancer Patients with MET amplification After Progression on First-Line EGFR Inhibitor Therapy

HUTCHMED Announces US$608 million Divestment of Non-Core Joint Venture

HUTCHMED to Receive Milestone Payment from Takeda following First European Reimbursement for FRUZAQLA® (fruquintinib)

Performance Overview